Scinai Secures Up to $10M Equity Line with Yorkville
Ticker: SCNI · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $15.0 million, $108,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-financing, capital-raise, standby-agreement
TL;DR
Scinai just inked a $10M equity line with Yorkville, giving them cash runway for 3 years.
AI Summary
On September 10, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. This agreement allows Scinai to sell up to $10 million of its ordinary shares to Yorkville over a period of 36 months, providing potential future capital for the company.
Why It Matters
This agreement provides Scinai with a flexible source of capital, potentially enabling it to fund ongoing operations and development without immediate dilution.
Risk Assessment
Risk Level: medium — Standby equity agreements can lead to significant dilution if the company's stock price declines, and the terms of the agreement should be carefully reviewed.
Key Numbers
- $10.0M — Standby Equity Facility (Maximum capital available from Yorkville over 36 months.)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- YA II PN, LTD. (company) — Purchaser in Equity Agreement
- $10 million (dollar_amount) — Maximum amount under Equity Purchase Agreement
- September 10, 2025 (date) — Date of Equity Purchase Agreement
- 36 months (duration) — Term of Equity Purchase Agreement
FAQ
What is the purpose of the Standby Equity Purchase Agreement?
The agreement provides Scinai Immunotherapeutics Ltd. with a flexible source of capital, allowing it to sell ordinary shares to YA II PN, LTD. over a period of 36 months.
Who is the counterparty to the Standby Equity Purchase Agreement?
The counterparty is YA II PN, LTD., a Cayman Islands exempt limited partnership.
What is the maximum amount Scinai can raise under this agreement?
Scinai can sell up to $10 million of its ordinary shares under the agreement.
What is the duration of the Standby Equity Purchase Agreement?
The agreement is in effect for a period of 36 months.
What was Scinai Immunotherapeutics Ltd. formerly known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
Filing Stats: 1,070 words · 4 min read · ~4 pages · Grade level 16.2 · Accepted 2025-09-11 07:49:50
Key Financial Figures
- $15.0 million — rrence, an “Advance”) up to $15.0 million (the “Commitment Amount”) o
- $108,000 — mpany agreed to pay a commitment fee of $108,000 (the “Commitment Fee”) as f
Filing Documents
- ea0256954-6k_scinai.htm (6-K) — 20KB
- ea025695401ex99-1_scinai.htm (EX-99.1) — 230KB
- 0001213900-25-086668.txt ( ) — 252KB
Forward-Looking Statements
Forward-Looking Statements This Report contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon the Company’s present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For this reason, among others, you should not place undue reliance upon the Company’s forward-looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Report. EXHIBIT INDEX Exhibit No. Description 99.1 Standby Equity Purchase Agreement, dated as of September 10, 2025, between the Registrant and YA II PN, LTD . 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: September 11, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 3